Intraperitoneal anti-PD-L1 increases survival in a novel ovarian cancer model and its in vivo efficacy is influenced by baseline anti-tumor immunity of the host

被引：0
|
作者：
Mony, Jyothi
Zhang, Lixin
Tirodkar, Tejas
Elishaev, Esther
Brozick, Joan
Edwards, Robert P.
Vlad, Anda M.
机构：
[1] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA
[2] Magee Womens Res Inst, Pittsburgh, PA USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.OVCASYMP14-POSTER-THER-1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
THER-1434
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Talilmogene laherparepvec increases the anti-tumor efficacy of the anti PD-1 immune checkpoint blockade
    Piasecki, Julia
    Le, Tiep
    Ponce, Rafael
    Beers, Courtney
    CANCER RESEARCH, 2015, 75
  • [32] Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
    Lim, Soyeon
    Park, Jun-Hee
    Chang, Hyun
    INVESTIGATIVE AND CLINICAL UROLOGY, 2023, 64 (01) : 74 - 81
  • [33] Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1
    Illidge, T.
    Lipowska-Bhalla, G.
    Cheadle, E.
    Honeychurch, J.
    Poon, E.
    Morrow, M.
    Stewart, R.
    Wilkinson, R.
    Dovedi, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S776 - S776
  • [34] Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models
    Borodovsky, Alexandra
    Wang, Yanjun
    Ye, Minwei
    Shaw, Joseph C.
    Sachsenmeier, Kris
    Deng, Nanhua
    Goodwin, Kelly
    Clarke, James D.
    Goodwin, Richard
    Strittmatter, Nicole
    Hay, Carl
    Sah, Vasu
    Deborah, Lawson
    Reimer, Corinne
    Congreve, Miles
    Mason, Jonathan
    Marshall, Fiona
    Lyne, Paul
    Woessner, Richard
    CANCER RESEARCH, 2018, 78 (13)
  • [35] Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer
    Luo, Lianxiang
    Wu, Tong
    Ji, Miaorong
    Xiang, Jing
    Zou, Youwen
    Liao, Yinglin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 133
  • [36] Anti-PD-L1 and lenalidomide enhance anti-tumor immunity in cutaneous T cell lymphoma through targeting PD1+M2-like tumor-associated macrophages
    Querfeld, Christiane
    Wu, Xiwei
    Qin, Hanjun
    Yuan, Yate-Ching
    Su, Chingyu
    Zain, Jasmine
    Feng, Mingye
    Rosen, Steven
    Han, Zhen
    EUROPEAN JOURNAL OF CANCER, 2023, 190 : S4 - S4
  • [37] Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
    Park, Ji-Eun
    Kim, Seong-Eun
    Keam, Bhumsuk
    Park, Ha-Ram
    Kim, Soyeon
    Kim, Miso
    Kim, Tae Min
    Doh, Junsang
    Kim, Dong-Wan
    Heo, Dae Seog
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [38] A novel, tumor-targeted immunocytokine comprising an anti-PD-L1 Affimer® fused to IL-15 exhibits potent anti-tumor activity
    Juskaite, Victoria
    Avisetti, Deepa
    Jones, David H.
    Sobri, Ahmad
    Billenness, Gregory
    Buist, Hanna
    Tong, Tik Nga
    Yahya, Norhakim
    McLaughlin, Fiona
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [39] Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
    Balsitis, Scott
    Gali, Volodymyr
    Mason, Pamela J.
    Chaniewski, Susan
    Levine, Steven M.
    Wichroski, Michael J.
    Feulner, Michael
    Song, Yunling
    Granaldi, Karen
    Loy, James K.
    Thompson, Chris M.
    Lesniak, Jacob A.
    Brockus, Catherine
    Kishnani, Narendra
    Menne, Stephan
    Cockett, Mark I.
    Iyer, Renuka
    Mason, Stephen W.
    Tenney, Daniel J.
    PLOS ONE, 2018, 13 (02):
  • [40] LBL-024, an anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model.
    Huang, Xiao
    Sun, Jianming
    Qin, Yurong
    Lin, Huan
    Guan, Jing
    Lai, Shoupeng
    Kang, Xiaoqiang
    Ling, Hong
    CANCER RESEARCH, 2021, 81 (13)
12345